AUS
NZ
UK
CA
USA
IND
Healthcare
ASX Biotech Update: AI Radiation Planning and Healthcare Innovation
April 09, 2026 05:04 PM AEST| By SamBiotech sector developments highlight AI-driven radiation planning collaboration, showcasing integration of advanced technology with clinical expertise in healthcare systems.
Can Paradigm Biopharma (ASX:PAR) Reach Profit Soon?
April 09, 2026 03:44 PM AEST| By SamParadigm Biopharmaceuticals’ journey toward profitability highlights growth ambitions, financial challenges, and evolving biotech trends shaping its future direction.
Why Mesoblast (ASX:MSB) Is Gaining Attention in ASX 200 Healthcare Stocks
April 09, 2026 03:41 PM AEST| By SamMesoblast activity highlighted developments within the ASX healthcare sector, reflecting biotechnology innovation and evolving market participation across global medical industries.
Is RACura Oncology Limited (ASX:RAC) Building Strength in All Ordinaries Biotech Sector?
April 09, 2026 03:03 PM AEST| By SamRACura Oncology progresses share quotation, highlighting developments within the healthcare and biotechnology sector across the All Ordinaries index.
Is This Wireless Pacing Breakthrough Changing Heart Care?
April 09, 2026 02:58 PM AEST| By SamEBR Systems highlights strong progress in wireless cardiac pacing, driven by rising adoption, expanding physician training, and ongoing clinical advancements in heart failure treatment.
Telix Moves Quietly—But Could This Subtle ASX Update Matter More Than It Seems?
April 09, 2026 11:04 AM AEST| By SamTelix adds new shares to ASX listing, reflecting steady capital strategy within the healthcare sector.
ASX 200 Tech Star Under Pressure: Is Pro Medicus Losing Its Shine?
April 09, 2026 10:30 AM AEST| By SamPro Medicus faces valuation scrutiny despite strong growth, reflecting shifting sentiment within the ASX 200 healthcare technology sector.
ASX All Ordinaries Healthcare Stock: Cogstate Surge Sparks Fresh Debate
April 09, 2026 10:10 AM AEST| By SamCogstate shares surge on strong contract growth and healthcare demand, highlighting its role in the All Ordinaries healthcare technology sector.
AI Healthcare Buzz: Artrya Shares Surge on Imaging Momentum
April 09, 2026 10:02 AM AEST| By SamArtrya gains attention as AI-driven healthcare imaging demand rises, highlighting growth opportunities within the All Ordinaries and evolving medical technology sector.
Mesoblast (ASX:MSB) ASX 200 Biotech Sector Activity Explained?
April 09, 2026 03:12 AM AEST| By SamMesoblast reflects ASX 200 and ASX 300 biotechnology sector activity, highlighting clinical development processes and healthcare innovation participation.
All Ordinaries: Paradigm Biopharma Files to List 6M Shares
April 08, 2026 08:09 PM AEST| By SamParadigm Biopharmaceuticals (ASX:PAR) applies for new shares on all ordinaries, adjusting the capital structure through options conversions while remaining compliant with ASX listing rules.
ASX Update: Artrya All Ordinaries Share Activity
April 08, 2026 05:53 PM AEST| By SamArtrya reflects ASX 300 and All Ordinaries healthcare technology sector activity through share quotation, highlighting capital structure processes and medical innovation.
ASX 200 Update: Telix Pharmaceuticals Sector Focus
April 08, 2026 02:44 PM AEST| By SamTelix Pharmaceuticals operates within the ASX 200 biotechnology sector, focusing on radiopharmaceutical development and contributing to healthcare market participation.
Mesoblast Seeks ASX 200 Quotation for New Shares
April 08, 2026 12:36 PM AEST| By SamMesoblast advances share quotation within the ASX 200 framework, reflecting capital structure adjustments and ongoing participation in the biotechnology sector.
Telix ASX 200 Healthcare Revenue Activity Update
April 07, 2026 02:28 PM AEST| By SamTelix operates within the healthcare sector, with radiopharmaceutical development and revenue activity reflecting ongoing innovation across ASX 200 and ASX 300 market segments.
ASX 20: What US tariffs mean for CSL and Mayne Pharma shares
April 07, 2026 02:23 PM AEST| By SamCSL and Mayne Pharma assess impact of US pharmaceutical tariffs, with both expecting limited operational disruption.
Beamtree (ASX:BMT) All Ordinaries AI Healthcare Sector Focus
April 07, 2026 01:50 PM AEST| By SamBeamtree operates in the healthcare technology sector, where AI-driven platforms and data systems support evolving medical services within the All Ordinaries market landscape.
Ramsay’s Big Shift: What’s Changing at RHC Now?
April 07, 2026 10:53 AM AEST| By SamRamsay Health Care’s strategic shift toward Australian operations highlights a renewed focus on efficiency, cost management and operational clarity, reshaping how the company is positioned within the evolving healthcare landscape.
ASX All Ordinaries Biotech Stock Update on Starpharma
April 07, 2026 09:48 AM AEST| By SamStarpharma’s share issuance highlights capital management within the biotechnology sector, reflecting research-driven operations and participation across All Ordinaries.
Can Lumos (ASX:LDX) Redefine Rapid Infection Testing?
April 02, 2026 10:20 PM AEDT| By SamLumos (ASX:LDX) advances US expansion with FebriDx, enhancing rapid infection diagnosis and supporting efficient clinical decisions across healthcare settings.
Advertise your brand on Kalkine Media